Concepedia

Author

Ray Gani

Boehringer Ingelheim (United Kingdom)ORCID

Also Known As

Gani,Ray, R Gani, R. Gani, Ray Gani

27

Publications

407

Citations

10

H-Index

27

Concepts

All Affiliations

Boehringer Ingelheim (United Kingdom)Imperial College LondonUniversidad Pablo de OlavidePfizer (United Kingdom)Biogen (United Kingdom)
RG

About

Ray Gani is an author at Boehringer Ingelheim (United Kingdom) specializing in medicine, public health, and outcomes research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

180

2

Public Health

4

4

158

3

Epidemiology

2

2

123

4

Biostatistics

1

1

10

5

Emergency Medicine

1

1

25

Ray Gani

×

11

Publications

397

Citations

10

H-Index

YearCitations

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Sonja Sorensen, Ray Gani, Paul Robinson,

Heart

2012

127

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

Ray Gani, Gavin Giovannoni, David O. Bates,

PharmacoEconomics

2008

103

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

Robert Hettle, Hanne Wouters, Jon G. Ayres,

Respiratory Medicine

2012

25

<p>The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies</p>

Chiara Azzari, Vincenzo Baldo, Sandro Giuffrida,

ClinicoEconomics and Outcomes Research

2020

24

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD

Ray Gani, Jane Griffin, Steve Kelly,

Primary Care Respiratory Journal

2010

22

Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain

Jesús Ruiz-Aragón, Ray Gani, Piedad Alvarez

Human Vaccines & Immunotherapeutics

2020

22

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain

Jesús Ruiz-Aragón, S. Márquez-Peláez, Ray Gani,

Vaccines

2022

20

Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland

Ulrich Heininger, Matthew Pillsbury, Salome Samant,

The Pediatric Infectious Disease Journal

2021

16

A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.

Huan Huang, Kelly Bell, Ray Gani,

PubMed

2018

14

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population

Anna Fochesato, Sara Sottile, Andrea Pugliese,

Vaccines

2022

14

Page 1